AR035946A1 - Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos - Google Patents

Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos

Info

Publication number
AR035946A1
AR035946A1 ARP020100942A ARP020100942A AR035946A1 AR 035946 A1 AR035946 A1 AR 035946A1 AR P020100942 A ARP020100942 A AR P020100942A AR P020100942 A ARP020100942 A AR P020100942A AR 035946 A1 AR035946 A1 AR 035946A1
Authority
AR
Argentina
Prior art keywords
treatment
compositions
disorders
preparation
posmenopausic
Prior art date
Application number
ARP020100942A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23057754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR035946(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR035946A1 publication Critical patent/AR035946A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Composición farmacéutica para usar en el tratamiento de trastornos menopáusicos y posmenopáusicos, caracterizada porque comprende una dosis de entre aproximadamente 0,25 mg y aproximadamente 0,1 mg de estrógenos conjugados y un vehículo farmacéutico. Dicha composición comprende una unidad de dosificación farmacéutica que comprende estrógenos conjugados en un vehículo farmacéuticamente aceptable, y el uso de una composición farmacéutica de acuerdo con la reivindicación 1, caracterizado porque es para la preparación de un medicamento útil para tratar o inhibir trastornos menopáusicos o posmenopáusicos en una mujer perimenopáusica, menopáusica o posmenopáusica que lo necesita, donde dicho medicamento es administrado oralmente a dicha mujer en forma continua e ininterrumpida durante el período de tratamiento.
ARP020100942A 2001-03-16 2002-03-15 Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos AR035946A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27670401P 2001-03-16 2001-03-16

Publications (1)

Publication Number Publication Date
AR035946A1 true AR035946A1 (es) 2004-07-28

Family

ID=23057754

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100942A AR035946A1 (es) 2001-03-16 2002-03-15 Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos

Country Status (18)

Country Link
US (2) US20020173499A1 (es)
EP (1) EP1368037A2 (es)
JP (1) JP2004524354A (es)
KR (1) KR20030090673A (es)
CN (2) CN1633299A (es)
AR (1) AR035946A1 (es)
AU (1) AU2002338277B2 (es)
BR (1) BR0208165A (es)
CA (1) CA2441252A1 (es)
EA (1) EA200301023A1 (es)
HU (1) HUP0500346A2 (es)
IL (1) IL157943A0 (es)
MX (1) MXPA03008366A (es)
NO (1) NO20034098L (es)
PL (1) PL364675A1 (es)
SG (1) SG154323A1 (es)
WO (1) WO2002078682A2 (es)
ZA (1) ZA200308029B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0208163A (pt) * 2001-03-16 2004-03-09 Wyeth Corp Terapia de reposição hormonal
EP1857110A3 (en) * 2001-03-16 2008-08-06 Wyeth Hormone replacement therapy
JP5143993B2 (ja) * 2003-03-26 2013-02-13 株式会社産学連携機構九州 エストロゲン様活性剤
JP2006522833A (ja) * 2003-04-11 2006-10-05 バー・ラボラトリーズ，インコーポレイテッド エストロゲンおよびプロゲスチンの投与法
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
BRPI0514628A (pt) * 2004-08-26 2008-06-17 Wyeth Corp composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar ou inibir doenças, métodos para baixar os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl; ou inibir avaria da parede vascular, para prover aumento de cognição ou neuroproteção; para tratar ou inibir estados doentios induzidos por radical livre, condições, e inchação ou erosão de junta; ou tratar ou inibir avaria de junta secundária a procedimentos artroscópicos ou cirúrgicos, e, composição farmacêutica
EP2289486A1 (en) * 2005-12-27 2011-03-02 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
CN101405006A (zh) * 2006-01-20 2009-04-08 梨树医药公司 治疗萎缩性阴道炎的方法
EP2004200A2 (en) * 2006-04-05 2008-12-24 Wyeth a Corporation of the State of Delaware Methods for prevention and treatment of conditions arising from local estrogen deficiency
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
WO2007143607A2 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
EP2044943A1 (en) * 2007-10-04 2009-04-08 Solvay Pharmaceuticals, Inc. Pharmaceutical compositions comprising esterified estrogens and methyltestosterone and method of using the same
WO2009061428A1 (en) * 2007-11-06 2009-05-14 Kline Ellis L Compositions and methods for treating parkinson's disease and related disorders
GB2475013A (en) * 2008-09-16 2011-05-04 Playtex Products Llc Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
KR101665261B1 (ko) 2015-08-06 2016-10-12 순천향대학교 산학협력단 위축성 질염의 치료용 조성물 및 위축성 질염의 진단용 마커 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1175468A (en) * 1967-10-19 1969-12-23 Merck Ag E Pharmaceutical Compositions
US3608075A (en) * 1969-07-28 1971-09-21 American Home Prod Compositions and methods of treating the menopausal syndrome
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
EP0322020A1 (en) * 1987-12-22 1989-06-28 Akzo N.V. Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis
US4980358A (en) * 1988-04-04 1990-12-25 George D. McAdory Method employing gonadal hormones and dopamine agonist intended for combined use in the improvement of lymphocyte function
IT1244697B (it) * 1991-02-01 1994-08-08 Chiesi Farma Spa Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale
IL107343A (en) * 1992-11-02 2003-10-31 Wyeth Corp PHARMACEUTICAL COMPOSITION FOR LOWERING BLOOD LIPID LEVEL, COMPRISING, 17alpha-DIHYDROEQUILENIN
AU692155B2 (en) * 1993-04-02 1998-06-04 Regents Of The University Of California, The Method and composition for treatment of osteoporosis
DE4326948C1 (de) * 1993-08-11 1994-11-17 Klaus Dr Med Umbreit Verwendung von natürlichen Östrogenen zur Verlangsamung des Alterungsprozesses bei Männern
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
AR014096A1 (es) * 1996-10-11 2001-02-07 Wyeth Corp 17 alfa,8,9-deshidroestradiol y 17 beta delta 8,9 deshidroestradiol, el uso de los mismos para la manufactura de un medicamento, una composicionfarmaceutica que los comprende y un procedimiento para su preparacion.
NZ500217A (en) * 1997-04-07 2001-11-30 American Home Prod Estra-5(10), 7-dienes for treating estrogen deficiency, osteoporosis and free radical induced disease states
CN1254341A (zh) * 1997-05-02 2000-05-24 美国家用产品公司 具有雌激素活性的3－羟基－雌－5(10)－烯－17－酮3－硫酸酯药用盐
DE69810617T2 (de) * 1997-05-05 2003-10-02 Wyeth Corp B-ring estratriendiol-sulfate
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
EP1080073A1 (en) * 1998-05-15 2001-03-07 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
WO2001000215A1 (en) * 1999-06-25 2001-01-04 Wake Forest University Compositions for treating or preventing neurodegeneration and cognitive decline
AR027878A1 (es) * 1999-11-05 2003-04-16 Wyeth Corp Metodos para identificar y utilizar compuestos inhibidores de amiloides
US20020151530A1 (en) * 2000-12-22 2002-10-17 Leonard Thomas W. Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
BR0208163A (pt) * 2001-03-16 2004-03-09 Wyeth Corp Terapia de reposição hormonal

Also Published As

Publication number Publication date
SG154323A1 (en) 2009-08-28
CA2441252A1 (en) 2002-10-10
US20060142258A1 (en) 2006-06-29
NO20034098L (no) 2003-11-13
BR0208165A (pt) 2004-03-30
MXPA03008366A (es) 2004-11-12
US20020173499A1 (en) 2002-11-21
AU2002338277B2 (en) 2007-11-22
JP2004524354A (ja) 2004-08-12
CN1633299A (zh) 2005-06-29
WO2002078682A2 (en) 2002-10-10
CN1879629A (zh) 2006-12-20
IL157943A0 (en) 2004-03-28
PL364675A1 (en) 2004-12-13
NO20034098D0 (no) 2003-09-15
HUP0500346A2 (hu) 2005-07-28
ZA200308029B (en) 2010-04-28
EP1368037A2 (en) 2003-12-10
KR20030090673A (ko) 2003-11-28
EA200301023A1 (ru) 2004-02-26
WO2002078682A3 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
AR031563A1 (es) Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
TR200002207T1 (tr) Slekoksib bileşikleri.
CO5261517A1 (es) Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis
BR9909672A (pt) uso de um composto medicinal ativo no preparo de um medicamento para o tratamento de hipertensão
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
PT100635A (pt) Forma de dosagem farmaceutica para a administracao retardada de um farmaco
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
AR029159A1 (es) Preparacion farmaceutica, envase que la contiene y uso en la preparacion de un medicamento util en la terapia de reemplazo hormonal
KR930007441A (ko) 의약품
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
AR008392A1 (es) Procedimiento que utiliza una porfirina verde para preparar un medicamento para prevenir o inhibir la formacion de placas arteriales y la composicionfarmaceutca obtenida por dicho procedimiento
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
KR970061244A (ko) 치매 치료용 약학 조성물
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
AR046036A1 (es) Composiciones de risedronato y metodos para su uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure